Acutus Medical: Up on FDA nod for U.S. trials to treat irregular heart rate condition

Acutus Medical

27/05/2021 13:45

** Shares of medical device maker  AFIB.O  rise 6.7% to
$15.25 in premarket trade 
    ** Co receives FDA approval to start U.S. atrial
fibrillation IDE trial with the AcQBlate force sensing ablation
system  urn:newsml:reuters.com:*:nGNX2qbsZt
    ** Atrial fibrillation is most common type of arrhythmia,
which causes an irregular and fast heart beat
    ** Trial to treat atrial fibrillation with therapeutic
technology and evaluate the safety of the system in the
treatment
    ** AcQBlate force catheter and system shows in real-time,
how much contact force is being applied during ablations - a
procedure to restore normal heart rhythm
    ** Enrollment for the trial to begin in the second half of
2021
    ** Stock down 50% YTD

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))